PubRank

Maria Francesca Donato

Author PubWeight™ 26.91‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007 3.58
2 Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. J Hepatol 2011 2.78
3 Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2009 2.33
4 A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007 1.83
5 Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003 1.78
6 A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012 1.29
7 Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 2012 1.26
8 Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. J Hepatol 2010 0.96
9 The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. Antivir Ther 2009 0.95
10 Prevention of hepatocellular carcinoma. Semin Liver Dis 2005 0.93
11 The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol 2013 0.91
12 The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. Antivir Ther 2011 0.82
13 Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers. Transpl Int 2012 0.81
14 The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. Antivir Ther 2009 0.79
15 Transient elastography identifies liver recipients with nonviral graft disease after transplantation: a guide for liver biopsy. Liver Transpl 2012 0.79
16 Antiviral therapy for HCV-associated cryoglobulinemic glomerulonephritis: case report and review of the literature. Kidney Blood Press Res 2013 0.79
17 Metabolic syndrome after liver transplantation: short-term prevalence and pre- and post-operative risk factors. Dig Liver Dis 2013 0.78
18 Transient elastography in the early prediction of progressive recurrent hepatitis C following liver transplantation. Hepatology 2010 0.77
19 Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C group study. Ann Hepatol 2012 0.76
20 Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C. Dig Liver Dis 2013 0.76
21 Might rapid virological response be used as a stopping rule in liver transplant recipients treated with pegylated interferon plus ribavirin? Liver Transpl 2008 0.75
22 Post-liver transplantation graft biopsies should not be used to assess the IL28B donor genotype in HCV recipients. J Hepatol 2012 0.75
23 Management of biliary anastomotic strictures after liver transplantation (BASALT study): A nationwide Italian survey. Liver Transpl 2017 0.75
24 The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies. Antivir Ther 2005 0.75
25 Twelve week post-treatment undetectable hepatitis C virus (HCV)-RNA by PCR assay predicts a sustained virological response to anti-HCV therapy independently from immunological status of the infected patients. J Antimicrob Chemother 2012 0.75